The Quantified Level of Circulating Prostate Stem Cell Antigen mRNA relative to GAPDH Level Is a Clinically Significant Indictor for Predicting Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy

Table 1

Patients’ clinicopathologic characteristics ( = 110).

Parameters	(%) or mean ± SD
Preoperative PSA (ng/mL)	11.7 ± 10.3
Prostate volume (mL)	35.5 ± 16.1
PSCA absolute titer	9531.2 ± 4272.5
>15,000	9 (8.2)
10,1001–1,5000	38 (34.5)
5001–10,000	51 (46.4)
<5000	12 (10.9)
PSCA/GAPDH ratio	1.1 ± 0.4
>1.5	11 (10.0)
1.1–1.5	56 (50.9)
0.5–1.0	35 (31.8)
>0.5	8 (7.3)
Gleason score sum	6.6 ± 0.8
Clinical stage T1	36 (32.7)
T2	56 (50.9)
T3	16 (14.6)
N1	2 (1.8)
Pathologic Gleason score sum	7.0 ± 0.9
Pathologic prostate volume (mL)	33.8 ± 15.2
Pathologic stage ≤T2b	63 (57.3)
≥T2c	47 (42.7)
N (+)	1 (0.9)
M1	4 (3.6)
Biochemical recurrence	24 (21.8)
Median time to biochemical recurrence (months)	7.0 (3–46)
Median follow-up duration (months)	42.1 ± 25.0